Company Overview and News

 
Trump's ethanol plan: Hype now, legal fights later

2018-10-12 channelnewsasia
President Donald Trump's hyping of a plan to boost ethanol demand drew cheers at an Iowa rally on Tuesday, but the oil refining industry has promised a lawsuit to block the move, so victory for Midwest farmers is far from certain.
CVI

 
Trump's ethanol plan: Hype now, legal fights later

2018-10-12 reuters
WASHNGTON/NEW YORK (Reuters) - President Donald Trump’s hyping of a plan to boost ethanol demand drew cheers at an Iowa rally on Tuesday, but the oil refining industry has promised a lawsuit to block the move, so victory for Midwest farmers is far from certain.
CVI

5
Icahn, CVR lose malpractice case against Wachtell Lipton law firm

2018-09-28 channelnewsasia
A federal judge in Manhattan on Friday dismissed an unusual lawsuit in which billionaire investor Carl Icahn accused the law firm Wachtell, Lipton, Rosen & Katz of malpractice related to his 2012 hostile takeover of CVR Energy Inc .
JBK GSC CVI TFG GSJ GS GLSSP GJS

5
Icahn, CVR lose malpractice case against Wachtell Lipton law firm

2018-09-28 reuters
NEW YORK (Reuters) - A federal judge in Manhattan on Friday dismissed an unusual lawsuit in which billionaire investor Carl Icahn accused the law firm Wachtell, Lipton, Rosen & Katz of malpractice related to his 2012 hostile takeover of CVR Energy Inc (CVI.N).
JBK GSC CVI TFG GSJ GS GLSSP GJS

5
Icahn, CVR lose malpractice case against Wachtell Lipton law firm

2018-09-28 reuters
NEW YORK, Sept 28 (Reuters) - A federal judge in Manhattan on Friday dismissed an unusual lawsuit in which billionaire investor Carl Icahn accused the law firm Wachtell, Lipton, Rosen & Katz of malpractice related to his 2012 hostile takeover of CVR Energy Inc.
JBK GSC CVI TFG GSJ GS GLSSP GJS

 
15
John Bean Technologies downgraded to underweight from neutral at J.P. Morgan

2018-09-21 marketwatch
A BNY Mellon strategist singles out areas of the market that stand to benefit in a protracted trade dispute.
NRCI NRC COTV STB NRCIA CVI NRCIB JBT ISRG WAGE

 
 
2
CVI / CVR Energy, Inc. 8-K (Current Report)

2018-09-04 sec.gov - 2
Document
CVI

63
Tracking Carl Icahn's Portfolio - Q2 2018 Update

2018-09-03 seekingalpha - 6
This article is part of a series that provides an ongoing analysis of the changes made to Carl Icahn’s 13F portfolio on a quarterly basis. It is based on Icahn’s regulatory 13F Form filed on 08/14/2018. Please visit our Tracking Carl Icahn’s Portfolio series to get an idea of his investment philosophy and our previous update for the fund’s moves during Q1 2018.
VLTCP CQP CVI SDRPQ FCX TPCA VMW ENZN AFNL HRI NWL EGN VLTCW CI WBT VKSC ARII LNG GLPI SD XRX IEP NAV CNDT SDOCQ HLF UAN DVMT ERI CVRR VLTC MTW SDRXP HTZ SDRXQ

 
CVI / CVR Energy, Inc. null

2018-08-28 sec.gov
Prosk
CVI

 
CVI / CVR Energy, Inc. null

2018-08-28 sec.gov
Proskauer Rose LLP Eleven T
CVI

2
CVI / CVR Energy, Inc. - Stock Institutional Ownership and Shareholders - Fintel.io

2018-08-01 fintel.io - 1
CVR Energy, Inc. (NYSE:CVI) has 171 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 90,265,668 shares. Largest shareholders include Icahn Carl C, Vanguard Group Inc, BlackRock Inc., Advisors Asset Management, Inc., Hennessy Advisors Inc, Bank of New York Mellon Corp, Renaissance Technologies LLC, State Street Corp, Dimensional Fund Advisors Lp, and Prudential Financial Inc.
HNNA STT PRU CVI PFK BLK PRH AEZS AEZ PJH

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to CVI / CVR Energy, Inc. on message board site Silicon Investor.

Corporate Vision (CVIA) Corporate Vision (CVIA) Corporate Vision (CVIA) The New Corporate Vision Inc. ( CVIA ) The New Corporate Vision Inc. ( CVIA ) The New Corporate Vision Inc. ( CVIA )
calvalley pet a M.CVI.A calvalley pet a M.CVI.A calvalley pet a M.CVI.A CVII is a VERY deirable u0026#034;shellu0026#034; in negotiation/NOW CVII is a VERY deirable u0026#034;shellu0026#034; in negotiation/NOW CVII is a VERY deirable u0026#034;shellu0026#034; in negotiation/NOW
CVI / KRT CVI / KRT CVI / KRT ICVI (now MTEI) ICVI (now MTEI) ICVI (now MTEI)
CVIA CVIA CVIA ICVI/ MOUNTAIN ENERGY (MTEI) ICVI/ MOUNTAIN ENERGY (MTEI) ICVI/ MOUNTAIN ENERGY (MTEI)
CUSIP: 12662P108